Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Launched by STANFORD UNIVERSITY · Dec 4, 2007

Keywords

ClinConnect Summary

This clinical trial is investigating new markers in the blood and tumors of patients with head and neck or lung cancers. The goal is to find out if these markers can help identify tumors that have low oxygen levels, a condition known as tumor hypoxia. Tumor hypoxia can make cancers more aggressive and harder to treat with standard therapies like radiation and chemotherapy. Researchers have already found some proteins that might indicate these low oxygen levels, and they want to confirm their effectiveness in a larger group of patients.

To participate in this study, individuals should have a confirmed diagnosis of squamous cell carcinoma of the head and neck or non-small cell lung cancer. The trial is open to adults aged 65 to 74, and family members of patients with head and neck cancer can also take part. Participants will need to sign a consent form that allows them to be part of the study and possibly contacted for follow-up in the future. Overall, this trial aims to improve understanding of how to better treat and manage aggressive tumors in these cancer types.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
• • Able to sign a Stanford IRB approved consent form
• Exclusion criteria:
• • Refuse or unable to sign an IRB approved consent form.
• • Refuse to be contacted in the future for follow up.